{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:24:33Z","timestamp":1787495073625,"version":"build-2736575974"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Chronic kidney disease (CKD) affects &amp;gt;10% of the global adult population and is associated with substantial cardiovascular morbidity and mortality. Sudden cardiac death (often precipitated by ventricular arrhythmias like torsades de pointes) is a leading cause of death in patients with CKD. Prolongation of the QT interval (a marker of delayed ventricular repolarization) is a significant risk factor for arrhythmia in patients with CKD, whether they are on dialysis or not. QT prolongation in CKD is multifactorial and may result from electrolyte imbalances, myocardial remodelling, autonomic dysfunction and exposure to QT-prolonging drugs. Patients on haemodialysis are particularly vulnerable to QT prolongation due to rapid intradialytic electrolyte and fluid shifts. Many drugs known to prolong the QT interval (including various selective serotonin reuptake inhibitors, antibiotics, antiemetics and antipsychotics) are frequently prescribed to patients with CKD, even though there are few data on their safety in this population. The results of several well-designed pharmaco-epidemiological analyses (all based on data from the US Renal Data System) have shown associations between QT-prolonging drugs and an elevated risk of sudden cardiac death among patients on dialysis. These findings are concerning, given the widespread use of such drugs. The objective of this narrative review is to critically evaluate the pathophysiological relevance, prevalence and cardiovascular consequences of QT-prolonging drug use in the CKD setting.<\/jats:p>","DOI":"10.1093\/ndt\/gfaf196","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T11:43:59Z","timestamp":1758627839000},"page":"614-624","source":"Crossref","is-referenced-by-count":2,"title":["QT-prolonging medications: prevalence of use and associated risks in CKD"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5384-9006","authenticated-orcid":false,"given":"Sophie","family":"Liabeuf","sequence":"first","affiliation":[{"name":"Amiens-Picardie University Hospital Pharmacoepidemiology Unit, Department of Clinical Pharmacology, , Amiens ,","place":["France"]},{"name":"MP3CV Laboratory, Jules Verne University of Picardie , Amiens ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Berdougo-Tritz","sequence":"additional","affiliation":[{"name":"GPR , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Augey","sequence":"additional","affiliation":[{"name":"GPR , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol\u00e8ne M","family":"Laville","sequence":"additional","affiliation":[{"name":"Amiens-Picardie University Hospital Pharmacoepidemiology Unit, Department of Clinical Pharmacology, , Amiens ,","place":["France"]},{"name":"MP3CV Laboratory, Jules Verne University of Picardie , Amiens ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A\u00efcha","family":"Mbarek","sequence":"additional","affiliation":[{"name":"GPR , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Deray","sequence":"additional","affiliation":[{"name":"GPR , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5771-5996","authenticated-orcid":false,"given":"Ziad A","family":"Massy","sequence":"additional","affiliation":[{"name":"Association pour l\u2019Utilisation du Rein Artificiel dans la r\u00e9gion parisienne , Paris ,","place":["France"]},{"name":"INSERM Unit 1018, Team 5, CESP, H\u00f4pital Paul Brousse, Paris-Saclay University and Versailles Saint-Quentin-en-Yvelines University , Villejuif ,","place":["France"]},{"name":"Ambroise Par\u00e9 University Hospital, APHP, Boulogne-Billancourt\/Paris Department of Nephrology, , and","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7369-7812","authenticated-orcid":false,"given":"Michel","family":"Jadoul","sequence":"additional","affiliation":[{"name":"Cliniques Universitaires Saint-Luc, Universit\u00e9 Catholique de Louvain Department of Nephrology, , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"2026033111015812700_bib1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int Suppl"},{"key":"2026033111015812700_bib2","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","article-title":"Chronic kidney disease","volume":"398","author":"Kalantar-Zadeh","year":"2021","journal-title":"Lancet"},{"key":"2026033111015812700_bib3","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1016\/S0140-6736(18)32225-6","article-title":"Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of disease study 2017","volume":"392","author":"GBD 2017 Risk Factor Collaborators","year":"2018","journal-title":"Lancet"},{"key":"2026033111015812700_bib4","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ekir.2023.01.037","article-title":"Health care resource utilization and related costs of patients with CKD from the United States: a report from the DISCOVER CKD retrospective cohort","volume":"8","author":"Sanchez","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2026033111015812700_bib5","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"key":"2026033111015812700_bib6","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1093\/cvr\/cvad083","article-title":"Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association","volume":"119","author":"Zoccali","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026033111015812700_bib7","doi-asserted-by":"publisher","first-page":"841","DOI":"10.34067\/KID.0000000000000447","article-title":"Polypharmacy in patients with CKD: a systematic review and meta-analysis","volume":"5","author":"Oosting","year":"2024","journal-title":"Kidney360"},{"key":"2026033111015812700_bib8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1053\/j.ajkd.2011.05.026","article-title":"Wasting and sudden cardiac death in hemodialysis patients: a post hoc analysis of 4D (Die Deutsche Diabetes Dialyse Studie)","volume":"58","author":"Drechsler","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"2026033111015812700_bib9","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2215\/CJN.08850811","article-title":"Modifiable practices associated with sudden death among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study","volume":"7","author":"Jadoul","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026033111015812700_bib10","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1136\/bjsm.2008.054734","article-title":"QTc: how long is too long?","volume":"43","author":"Johnson","year":"2009","journal-title":"Br J Sports Med"},{"key":"2026033111015812700_bib11","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1161\/01.CIR.84.3.1136","article-title":"The long QT syndrome. Prospective longitudinal study of 328 families","volume":"84","author":"Moss","year":"1991","journal-title":"Circulation"},{"key":"2026033111015812700_bib12","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.ihj.2015.02.030","article-title":"The classical \u201cR-on-T\u201d phenomenon","volume":"67","author":"Oksuz","year":"2015","journal-title":"Indian Heart J"},{"key":"2026033111015812700_bib13","doi-asserted-by":"publisher","first-page":"e13250","DOI":"10.1111\/ijcp.13250","article-title":"Incidence and outcomes of long QTc in acute medical admissions","volume":"72","author":"Mahmud","year":"2018","journal-title":"Int J Clin Pract"},{"key":"2026033111015812700_bib14","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1001\/archinternmed.2011.433","article-title":"QT-interval duration and mortality rate","volume":"171","author":"Zhang","year":"2011","journal-title":"Arch Intern Med"},{"key":"2026033111015812700_bib15","first-page":"i2732","article-title":"QT interval and drug therapy","volume":"353","author":"Drug and Therapeutics Bulletin","year":"2016","journal-title":"BMJ"},{"key":"2026033111015812700_bib16","doi-asserted-by":"crossref","first-page":"549","DOI":"10.5664\/jcsm.11474","article-title":"Genetic QT score as a predictor of sudden cardiac death in participants with sleep-disordered breathing in the UK Biobank","volume":"21","author":"Arora","year":"2025","journal-title":"J Clin Sleep Med"},{"key":"2026033111015812700_bib17","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jacc.2006.06.034","article-title":"QT interval duration remains a major risk factor in long QT syndrome patients","volume":"48","author":"Locati","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026033111015812700_bib18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/00000441-200603000-00008","article-title":"Severe primary hypothyroidism manifesting with torsades de pointes","volume":"331","author":"Schenck","year":"2006","journal-title":"Am J Med Sci"},{"key":"2026033111015812700_bib19","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1161\/CIRCULATIONAHA.106.678326","article-title":"Thyroid disease and the heart","volume":"116","author":"Klein","year":"2007","journal-title":"Circulation"},{"key":"2026033111015812700_bib20","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.hrthm.2024.05.013","article-title":"Proarrhythmic drugs, drug levels, and polypharmacy in victims of sudden arrhythmic death syndrome: an autopsy-based study from Denmark","volume":"21","author":"Pals\u00f8e","year":"2024","journal-title":"Heart Rhythm"},{"key":"2026033111015812700_bib21","article-title":"Risk categories for drugs that prolong QT & induce torsades de pointes (TdP)","author":"Woosley"},{"key":"2026033111015812700_bib22","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1007\/s11255-025-04479-1","article-title":"Association between elevated serum parathyroid hormone and QTc interval prolongation in chronic kidney disease patients","volume":"57","author":"Wang","year":"2025","journal-title":"Int Urol Nephrol"},{"key":"2026033111015812700_bib23","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2215\/CJN.04231206","article-title":"Kidney function, electrocardiographic findings, and cardiovascular events among older adults","volume":"2","author":"Kestenbaum","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026033111015812700_bib24","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/clc.20768","article-title":"QT prolongation is an independent predictor of mortality in end-stage renal disease","volume":"33","author":"Hage","year":"2010","journal-title":"Clin Cardiol"},{"key":"2026033111015812700_bib25","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1053\/ajkd.2002.32005","article-title":"Value of corrected QT interval dispersion in identifying patients initiating dialysis at increased risk of total and cardiovascular mortality","volume":"39","author":"Beaubien","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"2026033111015812700_bib26","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/cpt.3469","article-title":"The impact of QT-prolonging medications and drug-drug interactions on QTc interval prolongation in hospitalized patients: a case-crossover study","volume":"117","author":"Chien","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"2026033111015812700_bib27","doi-asserted-by":"publisher","first-page":"e015969","DOI":"10.1161\/JAHA.120.015969","article-title":"Use of QT prolonging medications by hemodialysis patients and individuals without end-stage kidney disease","volume":"9","author":"Assimon","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026033111015812700_bib28","doi-asserted-by":"publisher","first-page":"e248732","DOI":"10.1001\/jamanetworkopen.2024.8732","article-title":"Prescription and dispensation of QT-prolonging medications in individuals receiving hemodialysis","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026033111015812700_bib29","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.2215\/CJN.12991216","article-title":"Association of QT-prolonging medication use in CKD with electrocardiographic manifestations","volume":"12","author":"Snitker","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026033111015812700_bib30","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1111\/bcp.13738","article-title":"Evaluation of the adequacy of drug prescriptions in patients with chronic kidney disease: results from the CKD-REIN cohort","volume":"84","author":"Laville","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"2026033111015812700_bib31","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.genhosppsych.2023.10.016","article-title":"Atypical antipsychotics and the risk of sudden cardiac death among individuals receiving maintenance hemodialysis","volume":"85","author":"Nash","year":"2023","journal-title":"Gen Hosp Psychiatry"},{"key":"2026033111015812700_bib32","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1681\/ASN.0000000000000336","article-title":"Ondansetron and the risk of sudden cardiac death among individuals receiving maintenance hemodialysis","volume":"35","author":"Ismail","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"2026033111015812700_bib33","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.kint.2022.05.024","article-title":"Azithromycin use increases the risk of sudden cardiac death in patients with hemodialysis-dependent kidney failure","volume":"102","author":"Assimon","year":"2022","journal-title":"Kidney Int"},{"key":"2026033111015812700_bib34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1001\/jamacardio.2021.4234","article-title":"Analysis of respiratory fluoroquinolones and the risk of sudden cardiac death among patients receiving hemodialysis","volume":"7","author":"Assimon","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026033111015812700_bib35","doi-asserted-by":"publisher","first-page":"100618","DOI":"10.1016\/j.xkme.2023.100618","article-title":"QT-prolonging antibiotics, serum-to-dialysate potassium gradient, and risk of sudden cardiac death among patients receiving maintenance hemodialysis","volume":"5","author":"Pun","year":"2023","journal-title":"Kidney Med"},{"key":"2026033111015812700_bib36","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1681\/ASN.2018101032","article-title":"Comparative cardiac safety of selective serotonin reuptake inhibitors among individuals receiving maintenance hemodialysis","volume":"30","author":"Assimon","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2026033111015812700_bib37","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/pds.5428","article-title":"Proton pump inhibitors may enhance the risk of citalopram- and escitalopram-associated sudden cardiac death among patients receiving hemodialysis","volume":"31","author":"Assimon","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026033111015812700_bib38","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1093\/ndt\/gfac214","article-title":"The modifying effect of the serum-to-dialysate potassium gradient on the cardiovascular safety of SSRIs in the hemodialysis population: a pharmacoepidemiologic study","volume":"37","author":"Assimon","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2026033111015812700_bib39","doi-asserted-by":"publisher","first-page":"e003264","DOI":"10.1161\/JAHA.116.003264","article-title":"Which QT correction formulae to use for QT monitoring?","volume":"5","author":"Vandenberk","year":"2016","journal-title":"J Am Heart Assoc"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf196\/64395339\/gfaf196.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/4\/614\/64395339\/gfaf196.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/4\/614\/64395339\/gfaf196.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:02:02Z","timestamp":1774969322000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/41\/4\/614\/8263915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,9,25]]},"published-print":{"date-parts":[[2026,3,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf196","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2025,9,25]]}}}